The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Simply put, there's no incentive to be "emotionally supportive". In primary care, establishing a long term relationship between provider and patient evolves into a trusting relationship. Without the trust part, patient encounters are hollow, theatrical, and not supportive. There is no incentive to either...
Third party payers benefit the most from EHRs because it makes charts easier to audit The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.
The article did not focus on insulin. This is the hormonoal bad guy. Numerous studies looking at sulfonoureas vs glucophage, alpha-glucosidase inhibitors (Acarbose, etc) clearly demonstrate this. If you want real insight into the failures of this study and why, talk with me. Thomas...
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
The market is hungry for a weight loss drug with diabetes benefit. Currently, the FAD has phobia of the SEs with new drugs in this category Failure of Rimonabant was due to wrong direction of Sanofi Aventis in their approach to the FDA Taranabant may have better luck, especially if Merck take...
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes. With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.